The third-quarter earnings reports continue to roll in, and good news came in with the tide for some, but not all.
India's Lupin has begun recruiting R&D specialists for a new research center in the U.S. "It's a work in progress," says CEO Vinita Gupta. "We are attracting top-notch research and business development talents for this facility.
After taking a $500 million charge against 2012 earnings for Yaz and Yasmin-related litigation, Bayer has lost its patent fight with three generics makers intent on selling their own copycats.
A union fund is suing Warner Chilcott, Watson Laboratories and Lupin, claiming that their Loestrin 24 Fe patent settlements amounted to unfair market-sharing deals that cost payers money. Warner's key patent on the formula was weak, the fund claims, and the generics makers only backed away because Warner paid them to.
Lupin executives keep talking up their plans for U.S. expansion. Buying brands, buying companies, pumping up its own launches of generic drugs--the Indian drugmaker says it's going to pull out all the stops to build up its presence stateside.
Lupin is joining the list of genericsmakers looking toward branded drugs for growth. The Indian company is scouting for U.S. brands to buy, President Nilesh Gupta tells Bloomberg, particularly in the dermatology field.
Why isn't Cipla as big as Ranbaxy Laboratories? That's the central question of an Economic Times story profiling Chairman Yusuf Hamied and his company's recent changes. After years of promoting from
India's Lupin has made a second foray into Japan, striking a deal to buy the Tokyo-based injectables maker I'Rom Pharmaceutical. The buyout follows Lupin's acquisition of Kyowa Pharmaceuticals, which
Takeda Pharmaceutical is shopping in India, but whether it's buying is another story. Sources tell the Economic Times the Japanese drugmaker has been kicking tires over at Cipla and Lupin, both major
The media blitz focused on Medicis CEO Jonah Shacknai in the wake of the bizarre death of his girlfriend hasn't prevented the company from completing new development pacts. While a U.S. subsidiary of